VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools

Trends in Molecular Medicine

Volumn 9, Issue 5, 2003, Pages 211-217

  Pozo, David ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; AUTOIMMUNE DISEASE; BRAIN; IMMUNITY; IMMUNOMODULATION; INFLAMMATORY DISEASE; MOUSE; NONHUMAN; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STEADY STATE; TH2 CELL;

ANIMALIA; MURINAE;

EID: 0037495964     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(03)00049-2     Document Type: Review

References (63)

1. Moody, T.W. and Gozes, I. (2002) Twelfth annual summer neuropeptide conference, June 29 - July 3, 2002, Marco Island, Florida, USA. Neuropeptides 36, 371-386
2. Said, S. and Mutt, V. (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169, 1217-1218
3. Miyata, A. et al. (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164, 567-574
4. Sherwood, N.M. et al. (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev. 21, 619-670
5. Bellinger, D.L. et al. (1996) The significance of vasoactive intestinal polypetide (VIP) in immunomodulation. Adv. Neuroimmunol. 6, 5-27
6. Bellinger, D.L. et al. (1997) Vasoactive intestinal polypeptide (VIP) innervation of rat spleen, thymus, and lymph nodes. Peptides 18, 1139-1149
7. Cutz, E. et al. (1978) Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature 275, 661-662
8. Gomariz, R. et al. (1990) Demonstration of immunoreactivity vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus. Brain Behav. Immun. 4, 151-161
9. Weinstock, J. (1996) Vasoactive intestinal peptide regulation of granulomatous inflammation in murine Schistosomiasis mansoni. Adv. Neuroimmunol. 6, 95-105
10. Gomariz, R. et al. (1992) Occurence of vasoactive intestinal peptide (VIP) in lymphoid organs from rat and mouse. Ann. New York Acad. Sci. 650, 13-18
11. Gomariz, R.P. et al. (1994) Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. Regul. Pept. 50, 177-184
12. Gomariz, R.P. et al. (1994) Gene expression of VIP receptor in rat lymphocytes. Biochem. Biophys. Res. Commun. 203, 1599-1604
13. Abad, C. et al. (2002) Pituitary adenylate-cyclase-activating polypeptide expression in the immune system. Neuroimmunomodulation 10, 177-186
14. Martinez, C. et al. (1999) Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 93, 126-138
15. Delgado, M. and Ganea, D. (2001) Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166, 2907-2912
16. Harmar, A. et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50, 265-270
17. Laburthe, M. et al. (2002) VPAC receptors for VIP and PACAP. Receptors Channels 8, 137-153
18. Rawlings, S.R. and Hezareh, M. (1996) Pituitary adenylate cyclaseactivating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr. Rev. 17, 4-29
19. Pozo, D. et al. (1997) Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. Biochim. Biophys. Acta 1359, 250-262
20. 1 receptors. Ann. New York Acad. Sci. 921, 175-185
21. Spengler, D. et al. (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365, 170-175
22. Xia, M. et al. (1997) Novel cyclic peptide agonist of high potency and selectively for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281, 629-633
23. 1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J. Biol. Chem. 275, 24003-24012
24. Dewit, D. et al. (1998) The vasoactive intestinal peptide analogue RO 25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol. Lett. 60, 57-60
25. Delgado, M. et al. (2000) Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur. J. Immunol. 30, 3236-3246
26. 2 receptor subclass. Peptides 18, 403-408
27. 1 receptor. Peptides 18, 1555-1560
28. Gourlet, P. et al. (1995) Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur J. Pharmacol. 287, 7-11
29. Moro, O. and Lerner, E.A. (1997) Maxadilan, the vasodilator peptide from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J. Biol. Chem. 272, 966-970
30. Delgado, M. and Ganea, D. (2001) Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J. Immunol. 167, 966-975
31. Guerrero, J. et al. (1981) Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol. Cell. Endocrinol. 21, 151-160
32. O'Dorisio, M.S. et al. (1981) Vasoactive intestinal polypeptide stimulation of adenylate cyclase in purified human leukocytes. J. Immunol. 127, 2551
33. Reubi, J.C. (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues: clinical implications. Ann. New York Acad. Sci. 921, 1-25
34. Lara-Marquez, M.L. et al. (2001) Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 166, 2522-2530
35. Voice, J.K. et al. (2001) Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 15, 2489-2496
36. Pankhaniya, R. et al. (1998) Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes. FASEB J. 12, 119-127
37. Delgado, M. et al. (1996) Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 68, 27-38
38. Delgado, M. et al. (1999) VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. subsequent effect on IFN-γ synthesis by T cells. J. Neuroimmunol. 96, 167-181
39. Jabrane-Ferrat, N. et al. (1999) Enhancement by vasoactive intestinal peptide of γ-interferon production by antigen-stimulated type 1 helper T cells. FASEB J. 13, 347-353
40. Delgado, M. and Ganea, D. (2000) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. J. Immunol. 164, 1200-1210
41. 2 receptor. Exp. Hematol. 30, 1001-1009
42. Dorsam, G. and Goetzl, E.J. (2002) Vasoactive intestinal peptide receptor-1 (VPAC-1) is a novel gene target of the hemolymphopoietic transcription factor ikaros. J. Biol. Chem. 277, 13488-13493
43. Cortes, M. et al. (1999) Control of lymphocyte development by the ikaros gene family. Curr. Opin. Immunol. 11, 167-171
44. Pei, L. (1998) Molecular cloning of a novel transcriptional repressor protein of the rat type 1 vasoactive intestinal peptide receptor gene. J. Biol. Chem. 273, 19902-19908
45. Gomariz, P. et al. (2001) Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des. 7, 89-111
46. Ganea, D. and Delgado, M. (2002) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit. Rev. Oral Biol. Med. 13, 229-237
47. Delgado, M. et al. (1998) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor a transcriptional activation by regulating nuclear factor-κB and cAMP response element-binding protein/c-Jun. J. Biol. Chem. 273, 31427-31436
48. Martinez, C. et al. (1998) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc. Biol. 3, 591-601
49. Delgado, M. et al. (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: in vitro and in vivo studies. J. Immunol. 62, 2358-2367
50. Delgado, M. et al. (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation. J. Immunol. 162, 4685-4696
51. Delgado, M. et al. (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162, 1707-1716
52. Martinez, C. et al. (2002) Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc. Natl. Acad. Sci. USA 99, 1053-1058
53. Delgado, M. and Ganea, D. (2003) Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem. Biophys. Res. Commun. 301, 825-832
54. Pozo, D. et al. (2002) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-la production and mRNA expression. Cytokine 18, 35-42
55. Jiang, X. et al. (2002) VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J. Neuroimmunol. 133, 81-94
56. + T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 166, 2167-2172
57. Salomon, I. et al. (2002) Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol. 169, 2685-2693
58. Delgado, M. et al. (2003) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J. Leukoc. Biol. 73, 155-164
59. Delgado, M. et al. (2002) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J. 16, 1844-1846
60. 2 receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. USA 98, 13854-13859
61. Delgado, M. et al. (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7, 563-568
62. Bangale, Y. et al. (2002) Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice. Peptides 23, 2251-2257
63. Pozo, D. et al. (2000) Immunobiology of vasoactive intestinal peptide (VIP). Immunol. Today 21, 7-11